Switching to Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors

Kristy T. K. Lau, MSc;* Carlos K. H. Wong, PhD;* Ivan C. H. Au, BSc; Wallis C. Y. Lau, PhD; Kenneth K. C. Man, PhD; Celine S. L. Chui, PhD; Ian C. K. Wong, PhD

BACKGROUND: Evidence is limited in comparing treatment modification by substitution or add-on of glucose-lowering medications in patients with type 2 diabetes. This observational study aims to compare switching versus add-on of incretin-based drugs among patients with type 2 diabetes on background sodium-glucose cotransporter-2 inhibitors (SGLT2i).

METHODS AND RESULTS: This population-based, retrospective cohort study was conducted using the IQVIA Medical Research Data, including adults with type 2 diabetes on background SGLT2i from 2005 to 2020. New users of incretin-based drugs were allocated into the “Switch” group if they had discontinued SGLT2i treatment, or the “Add-on” group if their background SGLT2i was continued. Baseline characteristics of patients were balanced between groups. Study outcomes were all-cause mortality, cardiovascular diseases, kidney diseases, hypoglycemia, and ketoacidosis. Patients were observed from the index date of initiating incretin-based drugs until the earliest of an outcome event, death, or data cut-off date. Changes in anthropometric and metabolic parameters were also compared between groups from baseline to 12-month follow-up. A total of 2888 patients were included, classified into “Switch” (n=1461) or “Add-on” group (n=1427). Median follow-up was 18 months with 5183 person-years. Overall, no significant differences in the risks of study outcomes were observed between groups; however, patients in the “Add-on” group achieved significantly greater reductions in glycated hemoglobin, weight, percentage weight loss, and systolic blood pressure than their “Switch” counterparts.

CONCLUSIONS: Initiating incretin-based drugs as add-on among patients with type 2 diabetes on background SGLT2i was associated with risks of clinical end points comparable to switching treatments, in addition to better glycemic and weight control observed with the combination approach.

Key Words: add-on therapy ▪ dipeptidyl peptidase-4 inhibitor ▪ glucagon-like peptide-1 receptor agonist ▪ sodium-glucose cotransporter-2 inhibitor ▪ switching therapy ▪ type 2 diabetes

Considering the progressive nature of type 2 diabetes (T2D), patients often require multiple antidiabetic agents over their course of disease for optimal glycemic control, where the stepwise approach of initiating new glucose-lowering medications following the failure of existing therapy in meeting individualized glycated hemoglobin (HbA1c) targets remains the preferred regimen by various international guidelines.1–4 When treatment intensification is needed sequential to first-line metformin monotherapy,
**CLINICAL PERSPECTIVE**

**What Is New?**
- In this retrospective cohort study of patients with type 2 diabetes who were on background sodium-glucose cotransporter-2 inhibitors (SGLT2i), new users of incretin-based drugs were allocated into the “Switch” group if they had discontinued SGLT2i treatment, or the “Add-on” group if their background sodium-glucose cotransporter-2 inhibitors was continued.
- Over a median follow-up of 18 months, no significant differences in the risks of all-cause mortality, cardiovascular diseases, kidney diseases, hypoglycemia, and ketoacidosis were observed between groups.
- Patients in the “Add-on” group achieved significantly greater reductions in glycated hemoglobin, weight, percentage weight loss, and systolic blood pressure than their “Switch” counterparts.

**What Are the Clinical Implications?**
- While no significant differences in the risks of various clinical end points were identified between switching and add-on approaches in the current study, they should be interpreted with caution given the relatively short follow-up period and hence the small number of events that occurred.
- Meanwhile, several metabolic benefits of the combination (“Add-on”) approach were significantly greater than that of switching, including better glycemic control, reduction in weight and blood pressure over 12-month follow-up.
- Further studies with longer observation periods and randomized controlled trials are needed to clarify the risks and benefits of the 2 treatment modalities.

**Nonstandard Abbreviations and Acronyms**

| Abbreviation | Description |
|--------------|-------------|
| CCI          | Charlson Comorbidity Index |
| DPP4i        | dipeptidyl peptidase-4 inhibitors |
| ESKD         | end-stage kidney disease |
| GLP1RA       | glucagon-like peptide-1 receptor agonists |
| IMRD         | IQVIA Medical Research Data |
| IPTW         | inverse probability of treatment weights |
| SBP          | systolic blood pressure |
| SGLT2i       | sodium-glucose cotransporter-2 inhibitors |
| T2D          | type 2 diabetes |

Introduction of antidiabetic drugs with complementary mechanisms of action is recommended to help address the ominous octet of T2D pathophysiology. Among the different drug classes, sodium-glucose cotransporter-2 inhibitors (SGLT2i) offer substantial metabolic benefits beyond glycemic control, reducing the risks of cardiovascular diseases (CVD), progression of diabetic nephropathy, and mortality, in addition to promoting weight loss, lowering blood pressure (BP), and incurring a low risk of hypoglycemia. With increasing availability and its repositioning as a second-line glucose-lowering medication, it can be anticipated that an increasing number of patients will be put on a combination regimen of metformin and SGLT2i, and it would be intriguing to explore the preferred option for subsequent treatment intensification.

Incretin-based therapy consisting of dipeptidyl peptidase-4 inhibitors (DPP4i) and glucagon-like peptide-1 receptor agonists (GLP1RA) are alternative antidiabetic agents with demonstrated efficacy and general tolerability. While specific GLP1RA have exerted beneficial effects in terms of cardiovascular outcomes, especially lowering the risks of major adverse cardiovascular events and mortality, alongside considerable weight loss and BP reduction, DPP4i are less potent in the stimulation of incretin effect. Hence they are mostly associated with cardiovascular neutrality and clinical benefits of a smaller magnitude than GLP1RA. Because both drug classes act by promoting insulin secretion while suppressing that of glucagon in a glucose-dependent manner, they may compensate for the increased glucagon level and endogenous glucose production induced by SGLT2i to facilitate better glycemic control, and offer distinct mechanisms of action in targeting the metabolic defects of T2D that are complementary to those of metformin and SGLT2i, respectively, all without posing an additional risk of hypoglycemia. Accordingly, incretin-based drugs appear to be an attractive option over sulfonylureas or thiazolidinediones as treatment intensification, with respect to cardiorenal outcomes, clinical parameters, and risk of hypoglycemia.

Aside from the selection of antidiabetic agents based on patient preferences, cardiorenal status, and drug safety profile, the choice of drug initiation approach may also influence therapeutic efficacy via factors such as medication burden and patient adherence, correction of T2D pathophysiology, time to achieving individualized targets, clinical inertia, and overall cost-effectiveness that takes diabetic complications into account. A retrospective cohort study utilizing electronic medical records from the UK Clinical Practice Research Datalink (CPRD) found that among patients with T2D with inadequate glycemic control, adding a new glucose-lowering medication...
was associated with clinically significant reduction in HbA1c, which was not evident among those switching to another therapy or continuing with the original treatment.\(^\text{19}\) Recently, several clinical trials and meta-analyses have demonstrated that the combination of SGLT2i with incretin-based drugs may produce sub-additive or additive effects in glycemic control and improvements in metabolic parameters than either drug class with placebo\(^\text{20–26}\); yet, there is very limited evidence on the comparison of cardiorenal end points and mortality for combination therapy versus each treatment alone.\(^\text{27,28}\)

With reference to clinical guidelines recommending the substitution and/or addition of new anti-diabetic agents upon limited response to existing glucose-lowering therapy, as well as the research gap in evaluating any additional cardiorenal benefits of combining SGLT2i with incretin-based drugs over individual treatments and across different patient subgroups,\(^\text{9,10,12,14,18,29,30}\) this observational study aims to compare the all-cause mortality, cardiorenal outcomes, adverse effects, and changes in clinical parameters associated with incretin-based drugs as switching versus add-on therapy among patients with T2D on background SGLT2i in a real-life setting. Because glucose-lowering medications with duplicating mechanisms of action are generally not recommended in combination regimens,\(^8\) this study will consider the initiation of DPP4i or GLP1RA as substitution versus add-on to SGLT2i separately, and compare their safety and efficacy under respective treatment condition.

**METHODS**

**Data Source and Study Design**

This population-based, retrospective cohort study was conducted using the IMRD, a database comprising anonymized electronic primary health care records for 15 million patients from >750 general practices across the United Kingdom. IMRD incorporates data supplied by The Health Improvement Network, a proprietary database of Cegedim SA. It contains coded patient-level longitudinal information on demographics, symptoms, clinical diagnoses recorded using Read Codes, medication prescriptions, consultations, and anthropometric, clinical, and laboratory measures.

The data set is representative of the UK population by age, sex, medical conditions, and death rates adjusted for demographics, and has similar distribution of major chronic diseases, including diabetes, CVD, and mental illnesses, compared with the UK national statistics.\(^\text{31,32}\) Validity of the diagnoses of ischemic cerebrovascular events and chronic kidney disease (CKD) with Read Codes in The Health Improvement Network database has been confirmed,\(^\text{33,34}\) in addition to the accuracy of diabetes, hypertension, and CVD.\(^\text{35}\) Studies have utilized this database to explore the associations between glucose-lowering medications and mortality, macrovascular, and microvascular diseases in patients with T2D.\(^\text{36–38}\) We implemented a new user design based on IMRD data. New users of incretin-based drugs were first-time-ever users of GLP1RA or DPP4i drugs.

**Study Population**

General practices were included in the study from the latest of the following dates: 12 months after reporting acceptable mortality rates (a measure of data-recording quality), 12 months after beginning the use of electronic medical records, and study start date (January 1, 2005). This was to maximize data and recording quality.\(^\text{39}\)

People aged ≥18 years who had registered with an eligible general practice for a minimum of 12 months, with a record of T2D (using Read codes in Table S1 or Chapter 6.1 of the British National Formulary), and received 2 or more consecutive prescriptions for SGLT2i drug, were eligible for inclusion. Prescriptions of SGLT2i, GLP1RA, and DPP4i were identified using drug codes (Table S1). Eligible patients were categorized into the “Switch” group if they had initiated prescriptions for index incretin-based drugs, either GLP1RA or DPP4i drug, but discontinued that of SGLT2i, defined by either the absence of ongoing refills or a gap of 60 days; or “Add-on” group if they had received prescriptions for incretin-based drugs while not discontinuing that of background SGLT2i. Patients in the “Add-on” group with overlapping duration of 2 drug classes of <60 days were excluded. The date of initiating incretin-based drugs was considered the index date (baseline).

**Follow-Up Period**

Participants were followed up from the index date until the earliest of the following occurrences: outcome diagnosis, death, participant left the practice, practice ceased to contribute to the database, or the end of study (June 30, 2020).

**Baseline Covariates**

Baseline covariates of patients included age, sex, smoking status, drinking status, duration of T2D, duration of SGLT2i prescription, anthropometric and clinical measurements, laboratory readings, drug prescription within 1 year, and comorbidity status at baseline. Baseline body mass index, fasting glucose, HbA1c, average systolic blood pressure (SBP) and diastolic blood pressure within 1 year before baseline, total cholesterol to high-density lipoprotein-cholesterol ratio, low-density lipoprotein-cholesterol, and triglycerides were

---

Lau et al Switch vs Add-on of GLP1RA/DPP4i to SGLT2i in T2D

J Am Heart Assoc. 2022;11:e023489. DOI: 10.1161/JAHA.121.023489

3
taken from the closest reading before the index date. The estimated glomerular filtration rate (eGFR) was estimated by serum creatinine, age, and sex based on the Modification of Diet in Renal Disease Study formula. Use of insulin, oral antidiabetic drugs (metformin, sulfonylureas, and thiazolidinediones), antihypertensive drugs (in particularly angiotensin-converting enzyme inhibitors/angiotensin receptor blockers), lipid-lowering agents, antplatelets, and anticoagulants at baseline were identified using the prescription records within 1-year window before the index date. Past medical records of bariatric surgery were also extracted. Presence of any CVD, heart failure (HF), atrial fibrillation, hypertension, CKD, end-stage kidney disease (ESKD), diabetic retinopathy, peripheral neuropathy, mental or psychiatric disorder, and cancer were documented at baseline, as well as the comorbidity status determined by Charlson Comorbidity Index. The occurrence of hypoglycemia and ketoacidosis within 1 year before the index date was also recorded.

Outcome Measures
Study outcomes were all-cause mortality, CVD (composite of coronary heart disease, acute myocardial infarction, other ischemic heart disease, HF, stroke, transient ischemic attack, and peripheral vascular disease), HF (an outcome of interest with SGLT2i use), CKD, ESKD, hypoglycemia, and ketoacidosis by treatment groups. Outcome events and comorbidities were analyzed individually to generate model estimates, which were then pooled into a single estimate using Rubin’s rules.

Statistical Analysis
To account for incomplete baseline data, multiple imputation by chained equations was performed. Each missing baseline datum was imputed 5 times by random chained equation using other known baseline covariates. Five complete imputed data sets were analyzed individually to generate model estimates, which were then pooled into to a single estimate using Rubin’s rules.

For confounding adjustment, inverse probability of treatment weights (IPTW) using the propensity score was applied to balance covariates across 2 treatment groups. Logistic regression models were fitted by using the indicator variables of treatment group as the dependent variable and baseline covariates as independent variables. The predicted probability of receiving treatment based on the patient’s baseline covariates in the model is called propensity score. Patients with similar propensity scores were classified as having similar characteristics. We applied IPTW based on the propensity scores. Propensity score weights <1st percentile or >99th percentile in each group were trimmed. In the context of IPTW, multiple imputation followed by pooling treatment effect estimates across imputed data sets is the preferred approach.4 Balance of baseline covariates between groups were assessed using the standardized mean difference, with a value of >0.1 indicating balance.

Number of outcome events, person-years, and incidence rate with 95% PoissonCI for each treatment group were calculated. Cox proportional hazards regression model was used to examine the association between treatment groups and incidence of events, and estimate hazard ratios (HR) of treatment effects and their 95% CI. Proportional hazard assumption was tested by Schoenfeld residuals with P values adjusted by Bonferroni method. Secondary outcomes were compared between baseline and 12-month follow-up by paired t test within the same treatment group. Effects of switching from SGLT2i (dapagliflozin or empagliflozin) to either GLP1RA (exenatide or liraglutide) or DPP4i (sitagliptin, linagliptin, or alogliptin) were assessed, whereas the effects of initiating GLP1RA or DPP4i in addition to SGLT2i were investigated within the Add-on group.

Subgroup analyses were conducted based on incretin-based drug class (GLP1RA or DPP4i); stratification of baseline HbA1c (≤9% versus >9%); any prescription records of insulin, metformin, or sulfonylureas within 1 year before baseline; and types of SGTL2i (dapagliflozin or empagliflozin), GLP1RA (exenatide or liraglutide), and DPP4i (sitagliptin, linagliptin, or alogliptin) used (which were administered by >20% of patients). In sensitivity analyses, different scenarios were tested to assess the robustness of treatment effects, including (1) “as-treated” analysis to censor the follow-up period at the discontinuation of incretin-based drugs, subsequent switch from GLP1RA to DPP4i, or switch from DPP4i to GLP1RA; (2) competing risk analysis accounting for competing risk of death; (3) multiple imputation of missing baseline covariates without IPTW; and (4) complete-case with IPTW.

All statistical analyses were performed using Stata version 16.0 (StataCorp LP, College Station, Texas). All significance tests were 2-tailed and P values adjusted to 0.05 were taken to indicate statistical significance.
Ethical Approval
Use of the IMRD database has been approved by the NHS Health Research Authority (NHS Research Ethics Committee reference: 18/ LO/0441); in accordance with this approval, the study protocol was reviewed and approved by an independent Scientific Review Committee (reference number: 20SRC070). This study used de-identified data provided by patients as part of their routine primary care, and no informed consent was required for this study.

RESULTS
Among 31,171 adults with T2D receiving 2 or more consecutive prescription records of SGLT2i, a total of 2888 patients had initiated incretin-based drugs and received 2 or more consecutive prescription records of GLP1RA or DPP4i on or after January 1, 2005, of whom 1461 were switched from SGLT2i to incretin-based drugs (Switch group: GLP1RA n=412; DPP4i n=1049), while 1427 were prescribed with a combination of SGLT2i and incretin-based drugs (Add-on group: GLP1RA n=409; DPP4i n=1018) (Figure 1). Background SGLT2i therapy had been initiated for a mean of 1.4 (SD 1.1) years at baseline (Table 1). The 3 types of SGLT2i used were dapagliflozin (60.2%), empagliflozin (27.7%), and canagliflozin (12.1%). Over half (52.6%) of the patients used exenatide for GLP1RA initiation, followed by liraglutide (32.3%), dulaglutide (10.7%), and lixisenatide (4.4%). For patients initiating DPP4i, 39.2% used sitagliptin, 25.0% used linagliptin, 24.6% used alogliptin, 10.8% used saxagliptin, and 0.3% used vildagliptin. Baseline characteristics of patients in the 2 treatment groups after multiple imputation and weighting are listed in Table 1. Overall, the mean age of this cohort was 57.9 (SD 11.2) years, with baseline HbA1c of 9.0% (1.5%), duration of T2D for 8.7 (6.4) years, and Charlson Comorbidity Index of 4.1 (1.9). Demographic and clinical characteristics of patients were balanced between groups. Data completion rates of baseline covariates are detailed in Table S2.

The median follow-up period of patients in Switch and Add-on groups were 19.2 (interquartile range, 9.1–34.6) and 17.0 (8.0–28.5) months, respectively (Table 2). After weighting, incidence rate of all-cause mortality during follow-up was 11.82 and 12.57 per 1000 person-years among Switch and Add-on users, respectively. Overall, there were no significant difference in risks of all-cause mortality (HR, 0.908 [95% CI, 0.541–1.523]; P=0.713), CVD (HR, 0.746 [95% CI, 0.464–1.198]; P=0.225), HF (HR, 1.238 [95% CI, 0.501–3.058]; P=0.644), CKD (HR, 1.128 [95% CI, 0.761–1.670]; P=0.549), ESKD (HR, 1.942 [95% CI, 0.205–18.433]; P=0.563), hypoglycemia (HR, 1.180 [95% CI, 0.595–2.342]; P=0.636), and ketoacidosis (HR, 0.854 [95% CI, 0.113–6.480]; P=0.879) between treatment groups (Table 3). Similar risks of outcome events were observed between the 2 groups across subgroup and sensitivity analyses (Tables S3 and S4, respectively). Test for proportional hazard assumption by Schoenfeld residuals showed there is no evidence that the proportional hazard assumption has been violated.

Changes in anthropometric and laboratory parameters from baseline to 12-month follow-up were also compared within each treatment group (Figure 2) and by differences between the 2 groups (Figure S1). A significantly greater reduction in mean HbA1c (−0.7% versus −0.5%, P<0.001) was observed in the Add-on group compared with the Switch group, which were also evident among DPP4i users. When stratified by glycemic control at baseline, considerably larger decreases in HbA1c were noted at 12-month follow-up among patients with baseline level of ≥9% than those with ≤9%. In addition, patients in the Add-on group managed to achieve greater median reduction in weight (−2.4 versus −0.7 kg, P<0.001) and percentage total weight loss (2.2% versus 0.5%, P<0.001) than those in the Switch group, regardless of the incretin-based drug class. A significantly larger decrease in body mass index (−0.8 versus −0.2 kg/m², P<0.001) was evident among Add-on versus Switch users, particularly with DPP4i. While within-group changes in SBP were statistically insignificant, a trend towards BP lowering among patients in the Add-on group resulted in a significant difference from those in the Switch group (−1.1 versus 0.5 mm Hg, P=0.047). Notably, a larger decrease in total cholesterol/high-density lipoprotein-cholesterol ratio was only significant among DPP4i users of Add-on versus Switch treatment groups. Overall, there were no significant differences in 12-month changes of DBP, low-density lipoprotein-cholesterol, triglycerides, and eGFR between the Switch and Add-on groups.

DISCUSSION
In this cohort of patients with T2D with inadequate glycemic control despite being on a background glucose-lowering therapy of SGLT2i and other antidiabetic agents, no significant differences in the risks of all-cause mortality, cardiorenal outcomes, and other clinical end points were identified between the initiation of incretin-based drugs as substitution or addition to the existing drug regimen. Nevertheless, treatment modification with the stepwise combination approach (add-on) resulted in significant improvements of several metabolic parameters over 12-month follow-up compared with replacing SGLT2i with another new drug class (switch).

To our knowledge, the study design of this “new user” retrospective cohort analysis is unique in terms
of comparing multiple clinical end points and metabolic changes with respect to the adjustment of treatment modalities and the selection of newer antidiabetic agents (namely, SGLT2i and incretin-based drugs). The current literature is limited and inconclusive on any additional benefits of combining SGLT2i with incretin-based drugs in reducing the macrovascular and microvascular complications of diabetes. While a post hoc analysis of DECLARE-TIMI 58 concluded that the addition of dapagliflozin to baseline use of GLP1RA could lower the risks of hospitalization for heart failure and a composite of cardiovascular mortality and hospitalization for heart failure versus placebo, another post hoc analysis of EXSCEL could only observe significant risk reduction in all-cause and cardiovascular death with the combination of exenatide plus SGLT2i versus either placebo or exenatide alone, alongside a trend towards reducing the risk of major adverse cardiovascular events.27,42 Regarding specific renal outcomes (composite of eGFR reduction, ESKD, or renal death; and new-onset albuminuria), the former study also demonstrated a trend towards benefit for the addition of dapagliflozin versus placebo to baseline DPP4i or GLP1RA therapy.42 Similarly, using sulfonylureas as an active comparator, an observational cohort study of propensity score-matched patients with T2D found that adding SGLT2i to background GLP1RA therapy could lower the risks of composite cardiovascular outcomes and hospitalization for heart failure.28

Figure 1. Flowchart of identifying eligible patients with type 2 diabetes who had initiated incretin-based drugs as substitution (“Switch”) or add-on (“Add-on”) to background SGLT2i therapy. DPP4i indicates dipeptidyl peptidase-4 inhibitors; GLP1RA, glucagon-like peptide-1 receptor agonists; and SGLT2i, sodium-glucose cotransporter-2 inhibitors.
| Baseline characteristics | Before weighting | Add-on after propensity score weighting | SMD | SMD |
|--------------------------|------------------|---------------------------------------|-----|-----|
| **Socio-demographics**   |                  |                                       |     |     |
| Sex (%)                  |                  |                                       | 0.15| 0.01|
| Female                   | 46.3%            | 50.0%                                 | 42.5%|     |
| Male                     | 53.7%            | 50.0%                                 | 57.5%|     |
| Age (mean±SD), y         | 57.9 (11.2)      | 58.8 (11.6)                           | 57.0 (10.8)| 0.16| 0.03|
| **Clinical characteristics (mean±SD)** |              |                                       |     |     |
| SBP, mm Hg               | 131.6 (13.9)     | 132.1 (13.8)                          | 131.1 (14.1)| 0.07| 0.00|
| DBP, mm Hg               | 77.9 (9.0)       | 77.8 (8.8)                            | 78.0 (9.3)| 0.02| 0.00|
| BMI, kg/m²               | 34.7 (7.0)       | 34.8 (7.0)                            | 34.5 (7.0)| 0.03| 0.01|
| <25                      | 4.9%             | 5.3%                                  | 4.5% | 0.07| 0.08|
| 25 to <30                | 22.4%            | 21.2%                                 | 23.7%|     |
| 30 to <35                | 28.8%            | 28.5%                                 | 29.0%|     |
| ≥35                      | 43.9%            | 45.0%                                 | 42.8%|     |
| Weight, kg               | 99.1 (21.9)      | 98.7 (22.0)                           | 99.5 (21.7)| 0.03| 0.01|
| TC, mmol/L               | 4.5 (1.2)        | 4.5 (1.1)                             | 4.5 (1.2)| 0.01| 0.02|
| LDL-C, mmol/L            | 2.7 (1.2)        | 2.7 (1.2)                             | 2.8 (1.1)| 0.04| 0.02|
| TC-HDL-C ratio           | 4.2 (1.5)        | 4.2 (1.5)                             | 4.2 (1.5)| 0.01| 0.00|
| Triglyceride, mmol/L     | 2.7 (2.0)        | 2.6 (1.9)                             | 2.7 (2.1)| 0.04| 0.03|
| Fasting glucose, mmol/L  | 11.1 (4.8)       | 11.1 (4.9)                            | 11.1 (4.8)| 0.00| 0.01|
| HbA1c, %                 | 9.0 (1.5)        | 9.0 (1.6)                             | 9.0 (1.4)| 0.02| 0.00|
| ≤7                       | 3.3%             | 3.8%                                  | 2.7% | 0.07| 0.05|
| >7 to 9                  | 54.4%            | 53.5%                                 | 55.4%|     |
| >9                       | 42.3%            | 42.7%                                 | 41.9%|     |
| Creatinine (serum), μmol/L | 74.7 (20.4)   | 75.5 (23.8)                           | 73.8 (16.3)| 0.08| 0.06|
| eGFR, mL/min per 1.73 m² | 114.1 (29.6)    | 112.3 (30.4)                          | 116.0 (28.7)| 0.12| 0.01|
| Urine ACR, mg/g          | 58.2 (257.5)     | 64.4 (303.9)                          | 51.5 (195.7)| 0.05| 0.00|
| **Lifestyle factors (%)**|                  |                                       |     |     |
| Smoking status           |                  |                                       | 0.03| 0.06|
| Nonsmoker                | 47.8%            | 47.6%                                 | 47.9%|     |
| Current smoker           | 16.6%            | 16.2%                                 | 17.1%|     |
| Ex-smoker                | 35.6%            | 36.1%                                 | 35.0%|     |
| Drinking status          |                  |                                       | 0.04| 0.02|
| Nondrinker               | 26.2%            | 26.9%                                 | 25.5%|     |
| Current drinker          | 67.6%            | 66.7%                                 | 88.4%|     |
| Ex-drinker               | 6.2%             | 6.3%                                  | 6.1% |     |
| **Comorbidity status (%)**|                 |                                       |     |     |
| Cardiovascular diseases   |                  |                                       | 19.0%| 20.5%| 17.4%| 0.08| 0.02|
| Heart failure            | 2.5%             | 2.9%                                  | 2.1% | 0.05| 0.02|
| Atrial fibrillation      | 4.7%             | 5.9%                                  | 3.6% | 0.11| 0.01|
| Hypertension             |                  |                                       | 59.0%| 60.3%| 57.7%| 0.05| 0.01|
| Chronic kidney disease   |                  |                                       | 19.6%| 21.8%| 17.4%| 0.11| 0.02|
| End-stage kidney disease |                  |                                       | 0.1% | 0.1%| 0.1% | 0.02| 0.01|
| Diabetic retinopathy     |                  |                                       | 20.7%| 19.7%| 21.7%| 0.05| 0.00|
| Peripheral neuropathy    |                  |                                       | 10.2%| 11.6%| 8.8% | 0.09| 0.01|
| Mental or psychiatric disorder |      |                                       | 19.2%| 19.6%| 18.9%| 0.02| 0.02|

(Continued)
Lau et al Switch vs Add-on of GLP1RA/DPP4i to SGLT2i in T2D

Contrary to the few existing studies that explored the cardiorenal outcomes and mortality of SGLT2i and incretin-based drug combination relative to placebo, either treatment alone, or an active comparator, this study focused on evaluating these effects on new users of GLP1RA or DPP4i who had received SGLT2i

Table 1. (Continued)

| Baseline characteristics | Before weighting | Switch (N=1461) | Add-on (N=1427) | SMD | SMD |
|--------------------------|-----------------|----------------|----------------|-----|-----|
| Cancer                   | 5.5%            | 6.0%           | 4.9%           | 0.05| 0.00|
| Hypoglycemia within 1 y  | 1.0%            | 1.2%           | 0.8%           | 0.05| 0.00|
| Ketoacidosis within 1 y  | 0.1%            | 0.1%           | 0.1%           | 0.02| 0.01|
| Charlson comorbidity index* | 4.1 (1.9) | 4.3 (2.0)       | 3.9 (1.8)       | 0.20| 0.03|
| Charlson comorbidity index*, (%) | 0.18         | 0.10          |               |     |     |
| 1–2                      | 19.3%           | 18.5%          | 20.0%          |     |     |
| 3                        | 24.4%           | 20.9%          | 27.9%          |     |     |
| 4 or above               | 56.4%           | 60.5%          | 52.1%          |     |     |
| Duration of type 2 diabetes, y | 8.7 (6.4)     | 8.8 (6.6)       | 8.6 (6.1)       | 0.03| 0.00|
| Treatment use within 1 y (%) |           |               |                |     |     |
| Insulin                  | 57.3%           | 61.3%          | 53.1%          | 0.17| 0.02|
| Basal insulin            | 11.3%           | 13.3%          | 9.1%           | 0.13| 0.10|
| Oral antidiabetic drugs  |                |                |                |     |     |
| Metformin                | 91.9%           | 92.1%          | 91.6%          | 0.02| 0.00|
| SU                       | 45.9%           | 50.8%          | 40.9%          | 0.20| 0.01|
| TZD                      | 8.3%            | 9.7%           | 6.9%           | 0.10| 0.01|
| Antihypertensive drugs   | 75.8%           | 76.5%          | 75.1%          | 0.03| 0.00|
| ACEI/ARB                 | 64.7%           | 65.0%          | 64.4%          | 0.01| 0.00|
| Lipid-lowering drugs     | 84.0%           | 82.8%          | 85.4%          | 0.07| 0.01|
| Antipatelet drugs        | 28.9%           | 29.6%          | 28.2%          | 0.03| 0.00|
| Anticoagulant            | 7.9%            | 9.8%           | 5.9%           | 0.15| 0.03|
| Bariatric surgery        | 0.5%            | 0.4%           | 0.5%           | 0.01| 0.02|
| Duration of SGLT2i, y    | 1.4 (1.1)       | 1.3 (1.1)       | 1.5 (1.2)       | 0.14| 0.02|
| Drug type (%)            |                |                |                |     |     |
| SGLT2i                   |                |                |                | 0.12| 0.03|
| Canagliflozin            | 12.1%           | 14.0%          | 10.2%          |     |     |
| Dapagliflozin (Propanediol) | 60.2%         | 58.8%          | 61.6%          |     |     |
| Empagliflozin            | 27.7%           | 27.2%          | 28.2%          |     |     |
| GLP1RA                   |                |                |                | 0.28| 0.04|
| Exenatide                | 52.6%           | 48.8%          | 56.5%          |     |     |
| Dulaglutide              | 10.7%           | 14.8%          | 6.6%           |     |     |
| Liraglutide              | 32.3%           | 32.5%          | 32.0%          |     |     |
| Lixisenatide             | 4.4%            | 3.9%           | 4.9%           |     |     |
| DPP4i                    |                |                |                | 0.10| 0.03|
| Sitagliptin              | 39.2%           | 39.5%          | 39.0%          |     |     |
| Vildagliptin             | 0.3%            | 0.6%           | 0.1%           |     |     |
| Saxagliptin              | 10.8%           | 11.0%          | 10.5%          |     |     |
| Linagliptin              | 25.0%           | 25.4%          | 24.7%          |     |     |
| Alogliptin               | 24.6%           | 23.6%          | 25.7%          |     |     |

ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; BMI, body mass index; DBP, diastolic blood pressure; DPP4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor agonists; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; SGLT2i, sodium glucose cotransporter-2 inhibitors; SMD, standardized mean difference; SU, sulfonylureas; TZD, thiazolidinedione; and Urine ACR, urine albumin-to-creatinine ratio.

*The calculation of Charlson Comorbidity Index does not include acquired immune deficiency syndrome (AIDS).
Table 2. Number and Incidence Rate of All-Cause Mortality, Cardiovascular Diseases, Heart Failure, Chronic Kidney Disease, End-Stage Kidney Disease, Hypoglycemia, and Ketoacidosis Events

| Events                        | Before weighting | After weighting |
|-------------------------------|------------------|-----------------|
|                               | Cumulative incidence | Crude incidence rate (Cases / 1000 person-y) | Median follow-up periods (Months) | Mean follow-up periods (Months) | Incidence rate (Cases/1000 person-y) | Estimate | 95% CI* |
|                               | Cases with event | Rate | Estimate | 95% CI* | Person-y | | | |
| Total (N=2888)                |                  |      |          |        |         |          |         |         |
| All-cause mortality           | 64               | 2.22% | 12.35 | (9.51, 15.77) | 5183 | 18 | 22 | 12.20 | (10.15, 14.48) |
| Cardiovascular diseases       | 75               | 3.21% | 18.43 | (14.49, 23.10) | 4070 | 17 | 21 | 19.53 | (16.58, 22.74) |
| Heart failure                 | 21               | 0.75% | 4.17 | (2.58, 6.37) | 5041 | 18 | 21 | 4.11 | (2.92, 5.51) |
| Chronic kidney disease        | 112              | 4.83% | 28.13 | (23.16, 33.85) | 3961 | 17 | 21 | 27.39 | (23.69, 31.23) |
| End-stage kidney disease      | 4                | 0.14% | 0.77 | (0.21, 1.98) | 5170 | 18 | 22 | 0.76 | (0.30, 1.44) |
| Hypoglycemia                  | 38               | 1.33% | 7.47 | (5.28, 10.25) | 5089 | 18 | 21 | 7.81 | (6.17, 9.68) |
| Ketoacidosis                  | 4                | 0.14% | 0.77 | (0.21, 1.98) | 5173 | 18 | 22 | 0.75 | (0.30, 1.44) |
| Switch (N=1461)               |                  |      |          |        |         |          |         |         |
| All-cause mortality           | 36               | 2.46% | 12.90 | (9.04, 17.87) | 2790 | 19 | 23 | 11.82 | (9.02, 15.08) |
| Cardiovascular diseases       | 37               | 3.19% | 17.06 | (12.02, 23.52) | 2168 | 19 | 22 | 17.04 | (13.28, 21.45) |
| Heart failure                 | 13               | 0.92% | 4.82 | (2.57, 8.24) | 2699 | 19 | 23 | 4.55 | (2.85, 6.74) |
| Chronic kidney disease        | 64               | 5.60% | 31.04 | (23.90, 39.63) | 2062 | 17 | 22 | 28.95 | (23.93, 34.70) |
| End-stage kidney disease      | 3                | 0.21% | 1.08 | (0.22, 3.15) | 2779 | 19 | 23 | 0.98 | (0.31, 2.22) |
| Hypoglycemia                  | 23               | 1.59% | 8.43 | (5.35, 12.65) | 2727 | 19 | 23 | 8.41 | (6.03, 11.22) |
| Ketoacidosis                  | 2                | 0.14% | 0.72 | (0.09, 2.59) | 2786 | 19 | 23 | 0.73 | (0.16, 1.81) |
| Add-on (N=1427)               |                  |      |          |        |         |          |         |         |
| All-cause mortality           | 28               | 1.96% | 11.70 | (7.77, 16.91) | 2393 | 17 | 20 | 12.57 | (9.64, 15.92) |
| Cardiovascular diseases       | 38               | 3.23% | 19.98 | (14.14, 27.42) | 1902 | 16 | 19 | 22.10 | (17.70, 27.09) |
| Heart failure                 | 8                | 0.57% | 3.42 | (1.47, 6.73) | 2342 | 17 | 20 | 3.67 | (2.17, 5.71) |
| Chronic kidney disease        | 48               | 4.07% | 25.01 | (18.44, 33.16) | 1919 | 16 | 20 | 25.85 | (21.41, 31.26) |
| End-stage kidney disease      | 1                | 0.07% | 0.42 | (0.01, 2.33) | 2391 | 17 | 20 | 0.53 | (0.08, 1.54) |
| Hypoglycemia                  | 15               | 1.06% | 6.35 | (3.55, 10.47) | 2362 | 17 | 20 | 7.20 | (5.01, 9.85) |
| Ketoacidosis                  | 2                | 0.14% | 0.84 | (0.10, 3.03) | 2387 | 17 | 20 | 0.77 | (0.16, 1.83) |

DPP4i indicates dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonists; and SGLT2i, sodium glucose cotransporter-2 inhibitors.

*95% CI of incidence rates were constructed by Poisson distribution.
therapy for a mean of 1.4 years, and attempted to answer the intriguing question of whether switching to another new drug class or adding it to the existing drug regimen would influence patient outcomes in real-world clinical practice. This research question is of clinical relevance because patient adherence could be affected by factors including pill burden, treatment complexity, and medication cost; whereas a combination of antidiabetic agents with distinct mechanisms of action could potentially offer additional benefits to glycemic and metabolic control by targeting different pathophysiological defects of T2D,6,7,14 which remains to be proven and justified. While no significant differences in the risks of developing various clinical end points between switching and add-on could be identified in the current study, they should be interpreted with caution given the relatively short follow-up period and hence the small number of events that occurred.

In theory, the combination of SGLT2i with incretin-based drugs could exert complementary actions on cardiorenal protection and ameliorating adverse effects, with SGLT2i mainly lowering the risks of HF and diabetic nephropathy via hemodynamic benefits, GLP1RA acting to reduce major adverse cardiovascular events with anti-atherogenic and anti-inflammatory properties, and DPP4i attenuating the elevated risk of genital infections associated with SGLT2i use through modulating the immune system.7,14,18,43,44 Furthermore, SGLT2i may compensate for the possible negative actions of GLP1RA and potential risk of specific DPP4i in HF progression, while incretin-based drugs may alleviate the development of ketoacidosis associated with SGLT2i use by counteracting its increased glucagon secretion and subsequent ketogenesis.14,29,45,46 Nevertheless, it has also been proposed that the production of ketone bodies induced by SGLT2i may partly be responsible for its decrease in cardiac and renal workload, and hence the observed clinical benefits; therefore, any complementary effects of SGLT2i and incretin-based drug combination may depend on the degree of glucagon suppression, duration of pharmacological treatment, and any changes in drug efficacy over time.45

Regarding the choice of treatment modality, our results were consistent with that of the retrospective cohort study utilizing the UK CPRD, demonstrating that the add-on approach could achieve HbA1c reduction substantially larger than that of switching therapy, when patients were showing limited response to the original drug regimen19, however, changes in other anthropometric and metabolic parameters have not been compared between the 2 treatment approaches. This study suggested that, in addition to better glycemic control, the stepwise combination (add-on) therapy could produce reduction in weight and SBP significantly larger than that of substituting SGLT2i with incretin-based drugs over 12-month follow-up, which were generally in line with several clinical trials observing greater improvements with the addition of GLP1RA or DPP4i to SGLT2i versus placebo add-on or either drug class alone.23,25,47–50 While these studies would be classified as the comparison between “adding a new drug class” and “continuing the original therapy,” our study provided further evidence to support the use of “combination therapy” (add-on) over “replacing SGLT2i with incretin-based drugs” (switching) in terms of metabolic changes.

With reference to the pharmacological profile of these 3 drug classes, it can be postulated that GLP1RA would exert compensatory effects on the increased glucagon level and endogenous glucose production of SGLT2i to further reduce the HbA1c level, promote additive weight loss via the suppression of appetite to counteract the reported increase in food intake associated with SGLT2i use, and produce a synergistic effect on BP lowering with vasodilation and mild natriuresis that are distinct from SGLT2i-induced natriuresis and reduction of intravascular volume.7,14,29,43 Notably, reduction in HbA1c has also been consistently shown to be sub-additive with the combination of SGLT2i and incretin-based drugs versus either treatment alone, which could be attributed to the interference of drugs combined and the failure of GLP1RA or DPP4i in adequately blocking the elevated endogenous glucose production of SGLT2i, especially at higher HbA1c levels.7,14,17,18,20,31 Yet, our results reinforced the proposition that add-on or combination therapy would facilitate better glycemic control, even when compared with switching from a drug class with “limited response” to another with different mechanisms of action.

Concerning the initiation of DPP4i to existing SGLT2i therapy, our study revealed that the add-on approach could result in significantly larger reduction in HbA1c,
weight, and total cholesterol/high-density lipoprotein-cholesterol ratio than that of substitution or switching. While some studies argued that beyond glycemic control, the addition of DPP4i to SGLT2i might not confer any additional benefits on weight loss, lowering BP, or improving the lipid profile compared with SGLT2i alone,^{14,18,20,22} our study suggested that the combination therapy would be preferred to discontinuing SGLT2i and replacing it with DPP4i. Consistent with the fact that DPP4i is weight neutral and generally less potent than GLP1RA (including the suppression of endogenous glucose production), initiation of the latter could produce more clinically relevant reduction in HbA1c, weight, and BP.^{10,13,14,18,49} Nonetheless, DPP4i may still offer renal benefits in terms of decreasing albuminuria,^{42} and can be an alternative to patients preferring an oral route of administration.

Utilizing the IMRD representative of the United Kingdom population, this study attempted to evaluate the clinical and metabolic outcomes of patients with T2D initiating incretin-based drugs as substitution (‘Switch’) or add-on (‘Add-on’) to background SGLT2i therapy.

Figure 2. Mean and 95% CI of 12-month changes in anthropometric and laboratory parameters of patients with type 2 diabetes who had initiated incretin-based drugs as substitution (‘Switch’) or add-on (‘Add-on’) to background SGLT2i therapy.

%WL indicates percentage weight loss; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; SBP, systolic blood pressure; SGLT2i, sodium-glucose cotransporter 2 inhibitors; and TC, total cholesterol. *Significant difference (P<0.05) in mean of change from baseline to 12-month follow-up.
SGLT2i therapy in the real-world setting. Various baseline characteristics of patients had been taken into account, which were further adjusted with multiple imputations and propensity score weighting to balance the confounding factors between groups. Despite such unique study design in addressing the clinical question of whether switching or add-on would be the preferred treatment approach, and the focus on newer antidiabetic agents with demonstrated cardiorenal safety or benefits, several limitations of this study should be acknowledged. First, given that SGLT2i is a relatively new drug class approved for T2D management, the follow-up period of new users of incretin-based drugs who had been on previous SGLT2i therapy would be fairly short, and hence the small number of events occurred over a median of 18 months. This could limit the interpretation of our results, because differences in cardiovascular or renal events might not be evident within this short observation period. Accordingly, our study might be underpowered to draw definite conclusions about cardiorenal outcomes, in addition to our limited sample size. Second, this patient cohort had relatively poor glycemic (mean HbA1c 9.0%) and metabolic control at baseline; thus the current findings might not be generalizable to other patient populations with different clinical characteristics. Furthermore, this patient cohort had a mean duration of diabetes of 8.7 years and were prescribed various glucose-lowering medications within 1 year at baseline; hence the results would not be applicable to patients with T2D at an earlier stage of the disease. Third, over half of the GLP1RA users in this cohort were prescribed exenatide, which is not associated with cardio- or renoprotective effects, while none were given semaglutide, which is associated with reduction in major adverse cardiovascular events, stroke, composite renal outcome, and mortality. Such drug type distribution might have influenced our results. Fourth, biological mechanisms of the greater metabolic benefits observed with the add-on approach versus switching therapy remain to be elucidated. Some unmeasured confounding factors might have also played a role in the significant differences, such as more intensive therapy and lifestyle management of the metabolic risk factors in patients managed by physicians pursuing the add-on approach. Lastly, cost-effectiveness of different treatment modalities and quality of life indices of patients were not evaluated in the current study, which would also be relevant in the decision-making process.

CONCLUSIONS

In this patient cohort with T2D with inadequate glycemic control on background SGLT2i therapy, no significant differences in the risks of developing various clinical end points could be identified in the initiation of incretin-based drugs as substitution (switching) or add-on to the existing drug regimen. Meanwhile, several metabolic benefits of the combination approach were significantly greater than that of switching, including the reduction of HbA1c, weight, and SBP over 12-month follow-up. Further studies with longer observation periods and randomized controlled trials are needed to clarify the risks and benefits of the 2 treatment modalities.

Acknowledgments

IMRD incorporates data from The Health Improvement Network (THIN), a Cegedim database. Reference made to THIN is intended to be descriptive of the data asset licensed by IQVIA. Use of the IMRD database has been approved by the NHS Health Research Authority (NHSCR-Ethics Committee reference: 18/LO/0441); in accordance with this approval, the study protocol was reviewed and approved by an independent Scientific Review Committee (reference number: 20SR0070). IMRD incorporates data from The Health Improvement Network (THIN), a Cegedim database. Reference made to THIN is intended to be descriptive of the data asset licensed by IQVIA. This study used de-identified data provided by patients as part of their routine primary care. CKHW and KTKL had the original idea for the study, contributed to the development of the study, reviewed the literature, and constructed the study design. CKHW and ICHA conducted the statistical analysis, and wrote the first draft of the manuscript. KTKL reviewed the literature and wrote the first draft of the manuscript. WCYL, KKCM, CSLC, and IKOW provided critical input to the study design. All authors contributed to the interpretation of the analysis, critically reviewed and revised the manuscript, and approved the final manuscript as submitted. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. CKHW is the guarantor of this study and has full access to all data in the study, and takes responsibility for the integrity of the data and accuracy of data analysis.

ARTICLE INFORMATION

Received November 23, 2021; accepted February 21, 2022.

Affiliations

Department of Pharmacology and Pharmacy (K.T.L., C.K.W., I.C.A., W.C.L., K.K.M., I.C.W.); and Department of Family Medicine and Primary Care, School of Clinical Medicine, (C.K.W.), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, New Territories, Hong Kong SAR, China (C.K.W., C.S.C., I.C.W.); Research Department of Policy and Practice, University College London School of Pharmacy, London, UK (W.C.L., K.K.M., I.C.W.); School of Nursing (C.S.C.) and School of Public Health (C.S.C.), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

Sources of Funding

None.

Disclosures

No financial relationships exist with any organizations that might have an interest in the submitted work in the previous 2 years. No other relationships or activities that could appear to have influenced the submitted work exist. CKHW reports receipt of research funding from the EuroGol Group Research Foundation, the Hong Kong Research Grants Council, and the Hong Kong Health and Medical Research Fund. KKCM reports receipt of CW Mapleton Fellowship and received personal fees from IQVIA Holdings, Inc., unrelated to this work. CSLC has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, and Amgen; personal fee from Primevigilance Ltd.; outside the submitted work. CKHW reports receipt of research funding from Wellcome Trust, United Kingdom; National Natural Science Fund of China, China; The Hong

J Am Heart Assoc. 2022;11:e023489. DOI: 10.1161/JAHA.121.023489 12
Kong Research Grants Council, The Research Fund Secretariat of the Food and Health Bureau, Narcotics Division of the Security Bureau of HKSSAR, Hong Kong; Bristol-Myers Squibb, Pfizer, Bayer, and Janssen, a Division of Johnson & Johnson Takeda. ICKW also reports research funding outside the submitted work from Amgen, GSK, Novartis, and the Hong Kong Health and Medical Research Fund, National Institute for Health Research in England, European Commission, National Health and Medical Research Council in Australia, and also received speaker fees from Janssen and Medice in the previous 3 years. The remaining authors have no disclosures to report.

Data Availability Statement
The IQVIA Medical Research Data (IMRD) were obtained from IQVIA. For further information on access to the database, please contact IQVIA (contact details can be found at https://www.iqvi.com/locations/united-kingdom/information-for-members-of-the-public-medical-research-data).

Supplemental Material
Data S1
Tables S1–S4
Figure S1

REFERENCES
1. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44:S111–S124. doi: 10.2337/dci20-0009
2. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41:2455–2533. doi: 10.1093/eurheartj/ehz486
3. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, MIngrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–2701. doi: 10.2337/dc18-0003
4. National Institute of Health and Care Excellence. Type 2 diabetes in adults: management. [Published online December 2, 2015]. https://www.nice.org.uk/guidance/ng28/chapter/Recommendations. Accessed March 9, 2022
5. Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care. 2015;38:373–375. doi: 10.2337/dc14-2517
6. Cerasi A, Emanuelli, Chovanes C, Škotnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. Diabetes Obes Metab. 2018;20:497–507. doi: 10.1111/dob.13108
7. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab. 2017;19:1553–1362. doi: 10.1111/dob.12982
8. Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunberger G, Einhorn D, Abrahamson J, Handelsman Y, Grunber
and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol. 2019;18:138. doi: 10.1186/s12933-019-0942-x

28. Dave Chintant V, Kim Seoyoung C, Goldfine Allison B, Glynn Robert J, Tong A, Paterno E. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Circulation. 2021;143:770–779. doi: 10.1161/CIRCULATIONAHA.120.047985

29. De Block C. SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination. Lancet Diabetes Endocrinol. 2018;6:349–352. doi: 10.1016/S2213-8587(18)30031-7

30. Goldenberg RM, Ahoja V, Clemens KK, Gilbert JD, Poddar M, Verma S. Practical considerations and rationale for glucagon-like peptide-1 receptor agonist plus sodium–dependent glucose cotransporter-2 inhibitor combination therapy in type 2 diabetes. Can J Diabetes. 2021;45:291–302. doi: 10.1016/j.cjd.2020.09.005

31. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of the Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19:251–255. doi: 10.14236/jhi.v19i4.820

32. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawsonson RA. Mortality in people with Type 2 diabetes in the UK. Diabet Med. 2006;23:516–521.

33. Denburg MR, Haynes K, Shults J, Lewis JD, Leonard MB. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN) database. Pharmacoepidemiol Drug Saf. 2010;19:579–585. doi: 10.1002/pds.1919

34. Ruigómez A, Martín-Merino E, Rodríguez LAG. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN) database. Pharmacoepidemiol Drug Saf. 2010;19:579–585. doi: 10.1002/pds.1919

35. Daly B, Touli KA, Thomas N, Gokhale K, Martin J, Webber J, Keerthy S, Thomas GN, Cheng KK, Narendran P, et al. All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: a population-based, open cohort study. PLoS Med. 2018;15:e1002488. doi: 10.15371/journal.pmed.1002488

36. Hall GC, McMahon AD, Carroll D, Home PD. Observational study of the association of first insulin type in uncontrolled type 2 diabetes with macrovascular and microvascular disease. Diabetes Metab. 2017;43:211–216. doi: 10.1016/j.diabet.2017.02.003

37. Touli KA, Harri W, Saravanapavan P, Willis BH, Marshall T, Kumerarendran B, Gokhale K, Ghosh S, Cheng KK, Narendran P, et al. All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: a population-based, open cohort study. Diabetes Metab. 2017;43:211–216. doi: 10.1016/j.diabet.2017.02.003

38. Touli KA, Willis BH, Marshall T, Kumerarendran B, Gokhale K, Ghosh S, Thomas GN, Cheng KK, Narendran P, Harri W, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the health improvement network database. J Clin Endocrinol Metab. 2017;102:1719–1725. doi: 10.1210/jc.2016-3446

39. Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf. 2013;22:64–69. doi: 10.1002/pds.3368

40. de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, Liew A, Michos ED, Navaneethan SD, Olowu WA, et al. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98:51–515. doi: 10.1016/j.kint.2020.06.019

41. Leyrat C, Seaman SR, White IR, Douglas I, Smeeth L, Kim J, Resche-Rigon M, Carpenter JR, Williamsson EJ. Propensity score analysis with partially observed covariates: how should multiple imputation be used? Stat Methods Med Res. 2017;26:3–19. doi: 10.1177/0962280217731032

42. Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yaniv I, Rosenzberg A, Wilding JPH, Leiter LA, Bhatt DL, et al. Cardiovascular outcomes with dapagliflozin by baseline glucose-lowering agents: post hoc analyses from DECLARE-TIMI 58. Diabetes Obes Metab. 2021;23:29–38. doi: 10.1111/dom.14179

43. Díaz-Trastoy O, Villar-Taibo R, Sifontes-Dubón M, Mozlo-Perhalv E, Bernabeu-Morín I, Cabezas-Agricola JM, Muñoz-Leira V, Peinó-García R, Martín-Sueiro A, García-López JM, et al. GLP1 receptor agonist and SGLT2 inhibitor combination: an effective approach in real-world clinical practice. Clin Ther. 2020;42:e1–e12. doi: 10.1016/j. clinth.2019.12.012

44. Ninčević V, Omanovic Kolaric T, Roguljic H, Kizvat T, Smolić M, Bilic Č. Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes. Int J Mol Sci. 2019;20:9831. doi: 10.3390/ijms20209831

45. Goncalves E, Dell’SH. Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk. Diabetes Therapy. 2018;9:919–926. doi: 10.1007/s13300-018-0420-6

46. Packer M. Should we be combining GLP-1 receptor agonists and SGLT2 inhibitors in treating diabetes? Am J Med. 2018;131:461–463. doi: 10.1016/j.amjmed.2017.11.052

47. Blonde L, Belousova L, Fainberg U, Garcia-Hernandez PA, Jain SM, Kaltoft MS, Mosenzon O, Nafach J, Pale PS, Rea R. Liraglutide as add-on to sodium–glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2020;22:929–937. doi: 10.1111/dob.13978

48. DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393. doi: 10.2337/dc14-2364

49. Jabbour SA, Frias JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care. 2018;41:2136–2146. doi: 10.2337/dc18-0680

50. Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–383. doi: 10.2337/dc14-1142

51. Ali AM, Martinez R, Al-Jobori H, Adams J, Triplitt C, DeFronzo R, Cersosimo E, Abdul-Ghani M. Combination therapy with canagliflozin plus iraglutide exerts additive effect on weight loss, but not on HbA1c, in patients with type 2 diabetes. Diabetes Care. 2020;43:1234–1241. doi: 10.2337/dc18-2460
SUPPLEMENTAL MATERIAL
## Data S1. STROBE Statement—Checklist of items that should be included in reports of cohort studies

| Item No | Recommendation | Page No |
|---------|----------------|---------|
| **Title and abstract** |  | |
| 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | 2-3 |
|  | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2-3 |
| **Introduction** |  | |
| 2 | Explain the scientific background and rationale for the investigation being reported | 5-7 |
| **Objectives** | 3 | State specific objectives, including any prespecified hypotheses | 7 |
| **Methods** |  | |
| 4 | Present key elements of study design early in the paper | 7-9 |
| 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 7-9 |
| 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | 7-9 |
|  | (b) For matched studies, give matching criteria and number of exposed and unexposed | 9-10 |
| 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 9-11 |
| 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 10-11 |
| **Bias** | 9 | Describe any efforts to address potential sources of bias | 11 |
| **Study size** | 10 | Explain how the study size was arrived at | Fig1 |
| **Quantitative variables** | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 12 |
| **Statistical methods** | 12 | (a) Describe all statistical methods, including those used to control for confounding | 11-13 |
|  | (b) Describe any methods used to examine subgroups and interactions | 12 |
|  | (c) Explain how missing data were addressed | 11 |
|  | (d) If applicable, explain how loss to follow-up was addressed | 9 |
|  | (e) Describe any sensitivity analyses | 12 |
| **Results** |  | |
| 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Fig1 |
|  | (b) Give reasons for non-participation at each stage | Fig1 |
|  | (c) Consider use of a flow diagram | Fig1 |
| 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 13-14 |
(b) Indicate number of participants with missing data for each variable of interest

(c) Summarise follow-up time (eg, average and total amount)

| Outcome data | 15* | Report numbers of outcome events or summary measures over time | 14-15 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 14-15 |
| | | (b) Report category boundaries when continuous variables were categorized | NA |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | NA |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | 14, Supp Tables 3-4 |

**Discussion**

| Key results | 18 | Summarise key results with reference to study objectives | 15 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 20 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 16-20 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 16-20 |

**Other information**

| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 22 |

*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting.

The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/).

Information on the STROBE Initiative is available at http://www.strobe-statement.org.
Table S1. Read codes of comorbidities and event outcomes.

**Cardiovascular diseases**

| Code     | Description                                           |
|----------|-------------------------------------------------------|
| G3...00  | Ischaemic heart disease                               |
| G3...11  | Arteriosclerotic heart disease                        |
| G3...12  | Atherosclerotic heart disease                         |
| G3...13  | IHD - Ischaemic heart disease                         |
| G30..00  | Acute myocardial infarction                           |
| G30..11  | Attack - heart                                        |
| G30..12  | Coronary thrombosis                                   |
| G30..13  | Cardiac rupture following myocardial infarction (MI)  |
| G30..14  | Heart attack                                          |
| G30..15  | MI - acute myocardial infarction                      |
| G30..16  | Thrombosis - coronary                                 |
| G30..17  | Silent myocardial infarction                          |
| G300.00  | Acute anterolateral infarction                        |
| G301.00  | Other specified anterior myocardial infarction        |
| G301000  | Acute anteroapical infarction                         |
| G301100  | Acute anteroseptal infarction                         |
| G301z00  | Anterior myocardial infarction NOS                    |
| G302.00  | Acute inferolateral infarction                        |
| G303.00  | Acute inferoposterior infarction                      |
| G304.00  | Posterior myocardial infarction NOS                   |
| G305.00  | Lateral myocardial infarction NOS                     |
| G306.00  | True posterior myocardial infarction                  |
| G307.00  | Acute subendocardial infarction                       |
| G307000  | Acute non-Q wave infarction                           |
| G307100  | Acute non-ST segment elevation myocardial infarction  |
| G308.00  | Inferior myocardial infarction NOS                    |
| G309.00  | Acute Q-wave infarct                                  |
| G30A.00  | Mural thrombosis                                      |
| G30B.00  | Acute posterolateral myocardial infarction            |
| G30X.00  | Acute transmural myocardial infarction of unspecif site|
| G30X000  | Acute ST segment elevation myocardial infarction      |
| G30y.00  | Other acute myocardial infarction                     |
| G30y000  | Acute atrial infarction                               |
| G30y100  | Acute papillary muscle infarction                     |
| G30y200  | Acute septal infarction                               |
| G30yz00  | Other acute myocardial infarction NOS                 |
| G30z.00  | Acute myocardial infarction NOS                       |
| G31..00  | Other acute and subacute ischaemic heart disease      |
| G310.00  | Postmyocardial infarction syndrome                    |
G310.11  Dressler's syndrome
G311.00  Preinfarction syndrome
G311.11  Crescendo angina
G311.12  Impending infarction
G311.13  Unstable angina
G311.14  Angina at rest
G311000  Myocardial infarction aborted
G311011  MI - myocardial infarction aborted
G311000  Unstable angina
G311200  Angina at rest
G311300  Refractory angina
G311400  Worsening angina
G311500  Acute coronary syndrome
G311z00  Preinfarction syndrome NOS
G312.00  Coronary thrombosis not resulting in myocardial infarction
G31y.00  Other acute and subacute ischaemic heart disease
G31y000  Acute coronary insufficiency
G31y100  Microinfarction of heart
G31y200  Subendocardial ischaemia
G31y300  Transient myocardial ischaemia
G31y200  Other acute and subacute ischaemic heart disease NOS
G32..00  Old myocardial infarction
G32..11  Healed myocardial infarction
G32..12  Personal history of myocardial infarction
G33..00  Angina pectoris
G330.00  Angina decubitus
G330000  Nocturnal angina
G330z00  Angina decubitus NOS
G331.00  Prinzmetal's angina
G331.11  Variant angina pectoris
G332.00  Coronary artery spasm
G33z.00  Angina pectoris NOS
G33z000  Status anginosus
G33z100  Stenocardia
G33z200  Syncope anginosa
G33z300  Angina on effort
G33z400  Ischaemic chest pain
G33z500  Post infarct angina
G33z600  New onset angina
G33z700  Stable angina
G33zz00  Angina pectoris NOS
G34..00  Other chronic ischaemic heart disease
G340.00  Coronary atherosclerosis
G340.11  Triple vessel disease of the heart
G340.12  Coronary artery disease
G340000  Single coronary vessel disease
G340100  Double coronary vessel disease
G341.00  Aneurysm of heart
G341.11  Cardiac aneurysm
G341000  Ventricular cardiac aneurysm
G341100  Other cardiac wall aneurysm
G341111  Mural cardiac aneurysm
G341200  Aneurysm of coronary vessels
G341300  Acquired atroventricular fistula of heart
G341z00  Aneurysm of heart NOS
G342.00  Atherosclerotic cardiovascular disease
G343.00  Ischaemic cardiomyopathy
G344.00  Silent myocardial ischaemia
G34y.00  Other specified chronic ischaemic heart disease
G34y000  Chronic coronary insufficiency
G34y100  Chronic myocardial ischaemia
G34y200  Other specified chronic ischaemic heart disease NOS
G34z.00  Other chronic ischaemic heart disease NOS
G35..00  Asymptomatic coronary heart disease
G350.00  Subsequent myocardial infarction
G350.00  Subsequent myocardial infarction of anterior wall
G351.00  Subsequent myocardial infarction of inferior wall
G353.00  Subsequent myocardial infarction of other sites
G35X.00  Subsequent myocardial infarction of unspecified site
G36..00  Certain current complication follow acute myocardial infarct
G360.00  Haemopericardium/current comp folow acut myocard infarct
G361.00  Atrial septal defect/curr comp folow acut myocardial infarct
G362.00  Ventric septal defect/curr comp fol acut myocardial infarct
G363.00  Ruptur cardiac wall w'out haemopericard/cur comp fol ac MI
G364.00  Ruptur chordae tendinae/curr comp fol acute myocard infarct
G365.00  Rupture papillary muscle/curr comp fol acute myocard infarct
G366.00  Thrombosis atrium,auric append&vent/curr comp foll acute MI
G37..00  Cardiac syndrome X
G38..00  Postoperative myocardial infarction
G380.00  Postoperative transmural myocardial infarction anterior wall
G381.00  Postoperative transmural myocardial infarction inferior wall
G382.00  Postoperative transmural myocardial infarction other sites
G383.00  Postoperative transmural myocardial infarction unspec site
G384.00  Postoperative subendocardial myocardial infarction
G38z.00  Postoperative myocardial infarction, unspecified
G39..00  Coronary microvascular disease
G3y..00 Other specified ischaemic heart disease
G3z..00 Ischaemic heart disease NOS
Gyu3.00 [X]Ischaemic heart diseases
Gyu3000 [X]Other forms of angina pectoris
Gyu3100 [X]Other current complications following acute myocard infarct
Gyu3200 [X]Other forms of acute ischaemic heart disease
Gyu3300 [X]Other forms of chronic ischaemic heart disease
Gyu3400 [X]Acute transmural myocardial infarction of unspecified site
Gyu3500 [X]Subsequent myocardial infarction of other sites
Gyu3600 [X]Subsequent myocardial infarction of unspecified site
1O1..00 Heart failure confirmed
2JZ..00 On optimal heart failure therapy
662f.00 New York Heart Association classification - class I
662g.00 New York Heart Association classification - class II
662h.00 New York Heart Association classification - class III
662i.00 New York Heart Association classification - class IV
8B29.00 Cardiac failure therapy
G58..00 Heart failure
G58..11 Cardiac failure
G580.00 Congestive heart failure
G580.11 Congestive cardiac failure
G580.12 Right heart failure
G580.13 Right ventricular failure
G580.14 Biventricular failure
G580000 Acute congestive heart failure
G580100 Chronic congestive heart failure
G580200 Decompensated cardiac failure
G580300 Compensated cardiac failure
G580400 Congestive heart failure due to valvular disease
G581.00 Left ventricular failure
G581.11 Asthma - cardiac
G581.13 Impaired left ventricular function
G581000 Acute left ventricular failure
G582.00 Acute heart failure
G583.00 Heart failure with normal ejection fraction
G583.11 HFNEF - heart failure with normal ejection fraction
G583.12 Heart failure with preserved ejection fraction
G584.00 Right ventricular failure
G58z.00 Heart failure NOS
G58z.12 Weak heart
G5y4z00 Post cardiac operation heart failure NOS
661M500 Heart failure self-management plan agreed
661N500 Heart failure self-management plan review
Heart failure 6 month review
Congestive heart failure monitoring
Heart failure annual review
Education about deteriorating heart failure
Admit heart failure emergency
Heart failure follow-up
Referral to rapid access heart failure clinic
Hypertensive heart&renal dis wth (congestive) heart failure
Hypertensive heart&renal dis+both(congestv)heart and renal fail
Pulmonary oedema - acute
Weak heart
Heart failure as a complication of care
Cardiorespiratory failure as a complication of care
Congestive cardiomyopathy
Cerebrovascular disease
Subarachnoid haemorrhage
Ruptured berry aneurysm
Subarachnoid haemorrhage from carotid siphon and bifurcation
Subarachnoid haemorrhage from middle cerebral artery
Subarachnoid haemorrhage from anterior communicating artery
Subarachnoid haemorrhage from posterior communicating artery
Subarachnoid haemorrhage from basilar artery
Subarachnoid haemorrhage from vertebral artery
Subarachnoid haemorrh from intracranial artery, unspecif
Subarachnoid haemorrhage NOS
Intracerebral haemorrhage
CVA - cerebrovascular accid due to intracerebral haemorrhage
Stroke due to intracerebral haemorrhage
Cortical haemorrhage
Internal capsule haemorrhage
Basal nucleus haemorrhage
Cerebellar haemorrhage
Pontine haemorrhage
Bulbar haemorrhage
External capsule haemorrhage
Intracerebral haemorrhage, intraventricular
Intracerebral haemorrhage, multiple localized
Lobar cerebral haemorrhage
Intracerebral haemorrhage in hemisphere, unspecified
Left sided intracerebral haemorrhage, unspecified
Right sided intracerebral haemorrhage, unspecified
Intracerebral haemorrhage NOS
Other and unspecified intracranial haemorrhage
G620.00  Extradural haemorrhage - nontraumatic
G621.00  Subdural haemorrhage - nontraumatic
G622.00  Subdural haematoma - nontraumatic
G623.00  Subdural haemorrhage NOS
G62z.00  Intracranial haemorrhage NOS
G63..00  Precerebral arterial occlusion
G63..11  Infarction - precerebral
G63..12  Stenosis of precerebral arteries
G630.00  Basilar artery occlusion
G631.00  Carotid artery occlusion
G631.11  Stenosis, carotid artery
G631.12  Thrombosis, carotid artery
G632.00  Vertebral artery occlusion
G633.00  Multiple and bilateral precerebral arterial occlusion
G634.00  Carotid artery stenosis
G63y.00  Other precerebral artery occlusion
G63y000  Cerebral infarct due to thrombosis of precerebral arteries
G63y100  Cerebral infarction due to embolism of precerebral arteries
G63z.00  Precerebral artery occlusion NOS
G64..00  Cerebral arterial occlusion
G64..11  CVA - cerebral artery occlusion
G64..12  Infarction - cerebral
G64..13  Stroke due to cerebral arterial occlusion
G640.00  Cerebral thrombosis
G640000  Cerebral infarction due to thrombosis of cerebral arteries
G641.00  Cerebral embolism
G641.11  Cerebral embolus
G641000  Cerebral infarction due to embolism of cerebral arteries
G64z.00  Cerebral infarction NOS
G64z.11  Brainstem infarction NOS
G64z.12  Cerebellar infarction
G64z000  Brainstem infarction
G64z100  Wallenberg syndrome
G64z111  Lateral medullary syndrome
G64z200  Left sided cerebral infarction
G64z300  Right sided cerebral infarction
G64z400  Infarction of basal ganglia
G65..00  Transient cerebral ischaemia
G65..11  Drop attack
G65..12  Transient ischaemic attack
G65..13  Vertebro-basilar insufficiency
G650.00  Basilar artery syndrome
G650.11  Insufficiency - basilar artery
G651.00 Vertebral artery syndrome
G651000 Vertebro-basilar artery syndrome
G652.00 Subclavian steal syndrome
G653.00 Carotid artery syndrome hemispheric
G654.00 Multiple and bilateral precerebral artery syndromes
G655.00 Transient global amnesia
G656.00 Vertebrobasilar insufficiency
G657.00 Carotid territory transient ischaemic attack
G65y.00 Other transient cerebral ischaemia
G65z.00 Impending cerebral ischaemia
G65z100 Intermittent cerebral ischaemia
G65zz00 Transient cerebral ischaemia NOS
G66..00 Stroke and cerebrovascular accident unspecified
G66..11 CVA unspecified
G66..12 Stroke unspecified
G66..13 CVA - Cerebrovascular accident unspecified
G660.00 Middle cerebral artery syndrome
G661.00 Anterior cerebral artery syndrome
G662.00 Posterior cerebral artery syndrome
G663.00 Brain stem stroke syndrome
G664.00 Cerebellar stroke syndrome
G665.00 Pure motor lacunar syndrome
G666.00 Pure sensory lacunar syndrome
G667.00 Left sided CVA
G668.00 Right sided CVA
G669.00 Cerebral palsy, not congenital or infantile, acute
G67..00 Other cerebrovascular disease
G670.00 Cerebral atherosclerosis
G670.11 Precerebral atherosclerosis
G671.00 Generalised ischaemic cerebrovascular disease NOS
G671000 Acute cerebrovascular insufficiency NOS
G671100 Chronic cerebral ischaemia
G671200 Generalised ischaemic cerebrovascular disease NOS
G672.00 Hypertensive encephalopathy
G672.11 Hypertensive crisis
G673.00 Cerebral aneurysm, nonruptured
G673000 Dissection of cerebral arteries, nonruptured
G673100 Carotico-cavernous sinus fistula
G673200 Carotid artery dissection
G673300 Vertebral artery dissection
G674.00 Cerebral arteritis
G674000 Cerebral amyloid angiopathy
| Code       | Description                                                                 |
|------------|-----------------------------------------------------------------------------|
| G675.00    | Moyamoya disease                                                            |
| G676.00    | Nonpyogenic venous sinus thrombosis                                           |
| G676000    | Cereb infarct due cerebral venous thrombosis, nonpyogenic                    |
| G677.00    | Occlusion/stenosis cerebral arts not result cerebral infarct                 |
| G677000    | Occlusion and stenosis of middle cerebral artery                             |
| G677100    | Occlusion and stenosis of anterior cerebral artery                           |
| G677200    | Occlusion and stenosis of posterior cerebral artery                          |
| G677300    | Occlusion and stenosis of cerebellar arteries                                |
| G677400    | Occlusion+stenosis of multiple and bilat cerebral arteries                   |
| G678.00    | Cereb autosom dominant arteriop subcort infarcts leukoenceph                 |
| G679.00    | Small vessel cerebrovascular disease                                         |
| G67A.00    | Cerebral vein thrombosis                                                     |
| G67B.00    | Reversible cerebral vasoconstriction syndrome                                |
| G67B.11    | Call-Fleming syndrome                                                       |
| G67y.00    | Other cerebrovascular disease OS                                             |
| G67z.00    | Other cerebrovascular disease NOS                                            |
| G68..00    | Late effects of cerebrovascular disease                                     |
| G680.00    | Sequelae of subarachnoid haemorrhage                                        |
| G681.00    | Sequelae of intracerebral haemorrhage                                       |
| G682.00    | Sequelae of other nontraumatic intracranial haemorrhage                     |
| G683.00    | Sequelae of cerebral infarction                                              |
| G68W.00    | Sequelae/other + unspecified cerebrovascular diseases                       |
| G68X.00    | Sequelae of stroke,not specfd as h'morrhage or infarction                   |
| G6y..00    | Other specified cerebrovascular disease                                     |
| G6z..00    | Cerebrovascular disease NOS                                                  |
| Gyu6.00    | [X]Cerebrovascular diseases                                                  |
| Gyu6000    | [X]Subarachnoid haemorrhage from other intracranial arteries                 |
| Gyu6100    | [X]Other subarachnoid haemorrhage                                           |
| Gyu6200    | [X]Other intracerebral haemorrhage                                          |
| Gyu6300    | [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs                |
| Gyu6400    | [X]Other cerebral infarction                                                 |
| Gyu6500    | [X]Occlusion and stenosis of other precerebral arteries                     |
| Gyu6600    | [X]Occlusion and stenosis of other cerebral arteries                        |
| Gyu6700    | [X]Other specified cerebrovascular diseases                                 |
| Gyu6C00    | [X]Sequelea of stroke:not specfd as h'morrhage or infarction                 |
| Gyu6D00    | [X]Sequelea/other unspecified cerebrovascular diseases                      |
| Gyu6E00    | [X]Subarachnoid haemorrh from intracranial artery, unspecif                  |
| Gyu6F00    | [X]Intracerebral haemorrhage in hemisphere, unspecified                      |
| Gyu6G00    | [X]Cerebr infarct due unsp occlus/stenos precerebr arteries                 |
| G6W..00    | Cereb infarct due unsp occlus/stenos precerebr arteries                     |
| G6X..00    | Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs                  |
| G73z000    | Intermittent claudication                                                   |
| G73z011    | Claudication                                                                |
G73..12  Ischaemia of legs
G73zz00  Peripheral vascular disease NOS
G73z.00  Peripheral vascular disease NOS
G73yz00  Other specified peripheral vascular disease NOS
G73..11  Peripheral ischaemic vascular disease
G73..00  Other peripheral vascular disease
G73..13  Peripheral ischaemia
2G63.00  Ischaemic toe
G702.00  Extremity artery atheroma
G742z00  Peripheral arterial embolism and thrombosis nos
G702z00  Extremity artery atheroma NOS
G76A.00  Arterial insufficiency
G73y100  Peripheral angiopathic disease EC NOS
R055011  [d]peripheral circulatory failure
G73y.00  Other specified peripheral vascular disease
14NB.00  H/O: peripheral vascular disease procedure
Gyu7400  [X]Other specified peripheral vascular diseases
7A56600  Percutaneous transluminal placement peripheral stent artery
G733.00  Ischaemic foot
G73z012  Vascular claudication
G734.00  Peripheral arterial disease
16I..00  Claudication distance

**Chronic kidney disease**
14D..11  Kidney disease
1Z10.00  Chronic kidney disease stage 1
1Z12.00  Chronic kidney disease stage 3
1Z13.00  Chronic kidney disease stage 4
1Z14.00  Chronic kidney disease stage 5
1Z1G.00  Chronic kidney disease stage 3B without proteinuria
K13z.00  Kidney and ureter disease NOS
S76..00  Injury to kidney
S760000  Kidney injury without open wound into cavity, unspecified
S760z00  Kidney injury without mention of open wound into cavity NOS

**Hypoglycaemia**
66A6.00  Last hypo. attack
66A7.00  Frequency of hypo. attacks
66A7000  Frequency of hospital treated hypoglycaemia
66A7100  Frequency of GP or paramedic treated hypoglycaemia
66Ad.00  Hypoglycaemic attack requiring 3rd party assistance
66Ad000  Hypo atck - atndn ambulan crew
66AJ200  Loss of hypoglycaemic warning
Recurrent severe hypos
Hypoglycaemic warning absent
Hypoglycaemic management discussed
Hypoglycaemia education
Hypoglycaemic coma
Insulin coma
Hypoglycaemic coma NOS
Hypoglycaemia unspecified
Hypoglycaemia unspecified NOS
Other hypoglycaemia
Post-prandial hypoglycaemia
Drug-induced hypoglycaemia without coma
Other hypoglycaemia
Post gastrointestinal tract surgery hypoglycaemia
Hypoglycaemic management discussed
Hypoglycaemia education
Dietary counselling in hypoglycaemia
Insulin dependent diabetes mellitus with hypoglycaemic coma
Type 1 diabetes mellitus with hypoglycaemic coma
Type 2 diabetes mellitus with hypoglycaemic coma
Non-insulin dependent diabetes mellitus with hypoglycaemic coma
Type II diabetes mellitus with hypoglycaemic coma
Other specified diabetes mellitus with ketoacidosis
Insulin dependent diabetes mellitus with ketoacidosis
Type II diabetes mellitus with hypoglycaemic coma

Ketoacidosis
Urine ketoacid level
Diabetes mellitus with ketoacidosis
Diabetes mellitus, juvenile type, with ketoacidosis
Diabetes mellitus, adult onset, with ketoacidosis
Other specified diabetes mellitus with ketoacidosis
Diabetes mellitus NOS with ketoacidosis
Diabetes mellitus with ketoacidotic coma
Diabetes mellitus, juvenile type, with ketoacidotic coma
Diabetes mellitus, adult onset, with ketoacidotic coma
Diabetes mellitus NOS with ketoacidotic coma
Malnutrition-related diabetes mellitus with ketoacidosis
| Code     | Description                                      |
|----------|--------------------------------------------------|
| C10EM00  | Type 1 diabetes mellitus with ketoacidosis       |
| C10EM11  | Type I diabetes mellitus with ketoacidosis      |
| C10EN00  | Type 1 diabetes mellitus with ketoacidotic coma  |
| C10EN11  | Type I diabetes mellitus with ketoacidotic coma  |
| C10FN00  | Type 2 diabetes mellitus with ketoacidosis       |
| C10FN11  | Type II diabetes mellitus with ketoacidosis      |
| C10FP00  | Type 2 diabetes mellitus with ketoacidotic coma  |
| C10FP11  | Type II diabetes mellitus with ketoacidotic coma  |
| C362600  | Metabolic ketoacidaemia                          |
| C362700  | Ketoacidaemia NEC                                |
Table S2. Data completion rates of type 2 diabetes (T2D) patients who had initiated incretin-based drugs as substitution (‘Switch’) or add-on (‘Add-on’) to background sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy before multiple imputation

| Baseline characteristics | Total (N = 2,888) | Switch (N = 1,461) | Add-on (N = 1,427) |
|--------------------------|-------------------|-------------------|-------------------|
| **Socio-Demographic (%; n)** |                  |                   |                   |
| Sex                      | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| Age                      | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| **Clinical Characteristics (%; n)** |                |                   |                   |
| SBP                      | 99.8% (2,882)     | 99.7% (1,457)     | 99.9% (1,425)     |
| DBP                      | 99.8% (2,882)     | 99.7% (1,457)     | 99.9% (1,425)     |
| LDL-C                    | 90.5% (2,614)     | 90.4% (1,321)     | 90.6% (1,293)     |
| TC/HDL-C Ratio           | 97.4% (2,814)     | 97.3% (1,422)     | 97.5% (1,392)     |
| Triglyceride             | 94.3% (2,724)     | 95.0% (1,388)     | 93.6% (1,336)     |
| BMI                      | 98.8% (2,854)     | 99.0% (1,446)     | 98.7% (1,408)     |
| Weight                   | 98.8% (2,854)     | 99.0% (1,446)     | 98.7% (1,408)     |
| Fasting Glucose          | 84.7% (2,446)     | 86.8% (1,268)     | 82.6% (1,178)     |
| HbA1c                    | 99.7% (2,880)     | 99.7% (1,456)     | 99.8% (1,424)     |
| Creatinine (Serum)       | 99.3% (2,869)     | 99.1% (1,448)     | 99.6% (1,421)     |
| eGFR                     | 99.3% (2,869)     | 99.1% (1,448)     | 99.6% (1,421)     |
| Urine ACR                | 77.7% (2,243)     | 79.5% (1,162)     | 75.8% (1,081)     |
| Smoking status           | 99.8% (2,883)     | 99.9% (1,459)     | 99.8% (1,424)     |
| Drinking status          | 96.5% (2,786)     | 97.1% (1,419)     | 95.8% (1,367)     |
| Charlson's Index⁠         | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| Duration of type 2 diabetes | 100.0% (2,888) | 100.0% (1,461)    | 100.0% (1,427)    |
| **Treatment use within 1 year (%)** |            |                   |                   |
| Insulin                  | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| Basal insulin            | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| Oral anti-diabetic drugs |                  |                   |                   |
| Metformin                | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| SU                       | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| TZD                      | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| Anti-hypertensive drugs  | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| ACEI/ARB                 | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| Lipid-lowering drugs     | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| Antiplatelet drugs       | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| Anticoagulant            | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| Bariatric surgery        | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
| Duration of SGLT2i       | 100.0% (2,888)    | 100.0% (1,461)    | 100.0% (1,427)    |
SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL-C = low-density lipoprotein-cholesterol; TC = total cholesterol; HDL-C = high-density lipoprotein-cholesterol; BMI = body mass index; HbA1c = glycated hemoglobin; eGFR = estimated glomerular filtration rate; urine ACR = urine albumin to creatinine ratio; SU = sulfonylureas; TZD = thiazolidinediones; ACEI = Angiotensin Converting Enzyme Inhibitor; ARB = Angiotensin Receptor Blockers; SGLT2i = sodium-glucose cotransporter-2 inhibitors
Table S3. Subgroup analysis of all-cause mortality, cardiovascular disease, heart failure, and chronic kidney disease.

| Subgroup         | All-cause mortality | Cardiovascular diseases | Heart failure | Chronic kidney disease |
|------------------|---------------------|-------------------------|--------------|------------------------|
|                  | HR                   | 95% CI                  | P-value      | HR                     | 95% CI                  | P-value      | HR          | 95% CI                  | P-value      |
| Overall          | 0.908                | (0.541, 1.523)          | 0.713        | 0.746                  | (0.464, 1.198)          | 0.225        | 1.238       | (0.501, 3.058)          | 0.644        | 1.128       | (0.761, 1.670)          | 0.549        |
| GLP-1RA          | 0.576                | (0.211, 1.567)          | 0.280        | 0.470                  | (0.194, 1.143)          | 0.096        | 0.446       | (0.080, 2.483)          | 0.357        | 1.212       | (0.576, 2.548)          | 0.613        |
| DPP4i            | 1.084                | (0.590, 1.991)          | 0.295        | 0.898                  | (0.514, 1.569)          | 0.705        | 1.942       | (0.602, 6.270)          | 0.267        | 1.094       | (0.691, 1.734)          | 0.701        |
| Dapagliflozin    | 0.884                | (0.482, 1.622)          | 0.691        | 0.828                  | (0.471, 1.456)          | 0.512        | 1.210       | (0.420, 3.482)          | 0.724        | 1.477       | (0.886, 2.462)          | 0.134        |
| Empagliflozin    | 0.751                | (0.259, 2.176)          | 0.597        | 0.621                  | (0.222, 1.742)          | 0.365        | 1.885       | (0.174, 20.363)         | 0.602        | 1.015       | (0.499, 2.065)          | 0.967        |
| Exenatide        | 0.551                | (0.100, 3.020)          | 0.492        | NA                    | NA                     | NA          | NA          | NA                       | 0.855        | (0.242, 3.012)          | 0.807        |
| Liraglutide      | 0.723                | (0.166, 3.152)          | 0.666        | 0.675                  | (0.147, 3.112)          | 0.615        | NA          | NA                       | 0.123        | (0.363, 4.190)          | 0.737        |
| Sitagliptin      | 0.831                | (0.305, 2.270)          | 0.718        | 0.623                  | (0.275, 1.412)          | 0.257        | 0.526       | (0.091, 3.025)          | 0.471        | 1.133       | (0.591, 2.172)          | 0.707        |
| Linagliptin      | 1.521                | (0.594, 3.896)          | 0.382        | 0.997                  | (0.311, 3.194)          | 0.995        | 4.626       | (0.588, 36.377)         | 0.145        | 0.997       | (0.419, 2.375)          | 0.995        |
| Alogliptin       | 1.709                | (0.422, 6.913)          | 0.452        | 1.406                  | (0.408, 4.844)          | 0.589        | NA          | NA                       | 1.393        | (0.353, 5.498)          | 0.636        |
| Baseline HbA1c≤9 | 0.568                | (0.278, 1.162)          | 0.121        | 0.802                  | (0.406, 1.583)          | 0.525        | 1.421       | (0.404, 5.000)          | 0.584        | 1.118       | (0.645, 1.940)          | 0.691        |
| Baseline HbA1c>9 | 1.461                | (0.652, 3.272)          | 0.357        | 0.777                  | (0.399, 1.514)          | 0.459        | 1.124       | (0.312, 4.054)          | 0.858        | 1.163       | (0.656, 2.063)          | 0.605        |
| Insulin*         | 1.187                | (0.650, 2.169)          | 0.577        | 0.688                  | (0.397, 1.192)          | 0.182        | 1.720       | (0.540, 5.471)          | 0.358        | 1.161       | (0.729, 1.849)          | 0.530        |
| Metformin*       | 0.791                | (0.449, 1.393)          | 0.417        | 0.727                  | (0.441, 1.200)          | 0.213        | 1.120       | (0.448, 2.796)          | 0.809        | 1.086       | (0.721, 1.636)          | 0.693        |
| SU*              | 0.877                | (0.406, 1.895)          | 0.738        | 0.680                  | (0.376, 1.232)          | 0.203        | 1.943       | (0.523, 7.224)          | 0.321        | 1.197       | (0.683, 2.099)          | 0.530        |

GLP1RA = glucagon-like peptide-1 receptor agonists; DPP4i = dipeptidyl peptidase-4 inhibitors; HbA1c = glycated hemoglobin; SU = sulfonylureas; HR = hazard ratio; CI = confidence interval; NA = not applicable

Notes:

* Significant at 0.05 level by Cox proportional hazard regression

# Drug use within 1 year prior to baseline

† There was no cardiovascular disease event in the ‘Switch’ group among exenatide users.
Table S4. Hazard ratio of all-cause mortality, cardiovascular diseases, heart failure, chronic kidney disease, end-stage kidney disease, hypoglycemia, and ketoacidosis events in sensitivity analysis.

| Events                                | Multiple imputation | Complete case with IPTW and trimmed propensity score |
|---------------------------------------|---------------------|------------------------------------------------------|
|                                       | HR                  | 95% CI      | P-value | HR                  | 95% CI      | P-value |
| All-cause mortality                   | 1.041 (0.635, 1.706)| 0.874       |         | 1.021 (0.518, 2.013)| 0.952       |
| Cardiovascular diseases               | 0.820 (0.521, 1.291)| 0.391       | 0.904 (0.519, 1.574)| 0.722       |
| Heart failure                         | 1.394 (0.580, 3.353)| 0.458       | 1.683 (0.528, 5.364)| 0.379       |
| Chronic kidney disease                | 1.260 (0.864, 1.836)| 0.230       | 0.937 (0.580, 1.514)| 0.791       |
| End-stage kidney disease              | 2.652 (0.284, 24.755)| 0.392      | 2.080 (0.219, 19.766)| 0.523       |
| Hypoglycemia                          | 1.342 (0.691, 2.607)| 0.385       | 0.808 (0.347, 1.883)| 0.622       |
| Ketoacidosis                          | 0.733 (0.101, 5.326)| 0.759       | 0.215 (0.021, 2.170)| 0.193       |

| Events                                | As-treated analysis | Competing risk         |
|---------------------------------------|---------------------|------------------------|
|                                       | HR                  | 95% CI      | P-value | SHR      | 95% CI      | P-value |
| All-cause mortality                   | 0.351 (0.066, 1.873)| 0.220      |         | NA       | NA          | NA       |
| Cardiovascular diseases               | 0.832 (0.508, 1.363)| 0.465       | 0.751 (0.467, 1.205)| 0.235       |
| Heart failure                         | 1.173 (0.460, 2.992)| 0.738       | 1.248 (0.506, 3.077)| 0.630       |
| Chronic kidney disease                | 1.152 (0.761, 1.743)| 0.504       | 1.131 (0.764, 1.675)| 0.537       |
| End-stage kidney disease              | NA                  | NA          | 1.949 (0.205, 18.506)| 0.561       |
| Hypoglycemia                          | 1.284 (0.615, 2.683)| 0.505       | 1.182 (0.596, 2.345)| 0.632       |
| Ketoacidosis                          | 0.917 (0.125, 6.737)| 0.932       | 0.867 (0.114, 6.583)| 0.890       |

IPTW = inverse probability of treatment weights; HR = hazard ratio; SHR = sub-hazard ratio; CI = confidence interval; NA = not applicable

Notes:
* Significant at 0.05 level by Cox proportional hazard regression
† There was no end-stage kidney disease event observed between baseline and the last date of drug prescription in the ‘Add-on’ group in as-treated analysis.
Figure S1. Mean and 95% confidence interval of 12-month changes in anthropometric and laboratory parameters of type 2 diabetes (T2D) patients who had initiated incretin-based drugs as substitution (‘Switch’) or add-on (‘Add-on’) to background sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy by patient subgroups

SGLT2i = sodium-glucose cotransporter-2 inhibitors; GLP1RA = glucagon-like peptide-1 receptor agonists; DPP4i = dipeptidyl peptidase-4 inhibitors; BMI = body mass index; %WL = percentage weight loss

Note:
# Drug use within 1 year prior to baseline
* Significant difference (p<0.05) in mean of change from baseline to 12-month follow-up between groups by univariate linear regression
SGLT2i = sodium-glucose cotransporter-2 inhibitors; GLP1RA = glucagon-like peptide-1 receptor agonists; DPP4i = dipeptidyl peptidase-4 inhibitors; SBP = systolic blood pressure; DBP = diastolic blood pressure

Note:

# Drug use within 1 year prior to baseline

* Significant difference (p<0.05) in mean of change from baseline to 12-month follow-up between groups by univariate linear regression
SGLT2i = sodium-glucose cotransporter-2 inhibitors; GLP1RA = glucagon-like peptide-1 receptor agonists; DPP4i = dipeptidyl peptidase-4 inhibitors; LDL-C = low-density lipoprotein-cholesterol; TC = total cholesterol; HDL-C = high-density lipoprotein-cholesterol

Note:

# Drug use within 1 year prior to baseline

* Significant difference (p<0.05) in mean of change from baseline to 12-month follow-up between groups by univariate linear regression
SGLT2i = sodium-glucose cotransporter-2 inhibitors; GLP1RA = glucagon-like peptide-1 receptor agonists; DPP4i = dipeptidyl peptidase-4 inhibitors; HbA1c = glycated hemoglobin

Note:

# Drug use within 1 year prior to baseline

* Significant difference (p<0.05) in mean of change from baseline to 12-month follow-up between groups by univariate linear regression
SGLT2i = sodium-glucose cotransporter-2 inhibitors; GLP1RA = glucagon-like peptide-1 receptor agonists; DPP4i = dipeptidyl peptidase-4 inhibitors; eGFR = estimated glomerular filtration rate

Note:
# Drug use within 1 year prior to baseline
* Significant difference (p<0.05) in mean of change from baseline to 12-month follow-up between groups by univariate linear regression